Morocco Market Size and Regulatory Load: Imports and Localization
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Morocco depends on imports for 85%–90% of its domestic medical device demand. On February 4, 2026, the Minister of Health and Social Protection, the Minister of Industry and Trade, the Director General of AMMPS, the President of the Confederation of Moroccan Enterprises (CGEM) and the President of the Moroccan Federation of the Health Industry (FMIS) jointly signed a 2026–2030 strategic framework agreement at the second Medical Devices Day, aimed squarely at reducing import dependence. For Chinese manufacturers the reading is two-fold: in the short term this remains an import-driven market where the registration track of Loi n° 84-12 is the only practical door, and in the mid term localization deserves a real evaluation as policy support builds. The market-entry strategy should therefore be designed in segments along this time axis, with the import track carrying the near-term revenue plan and a structured monitoring mechanism carrying the localization option. Companies that treat the market as static will miss the policy window; companies that treat it as already transformed will mis-price the present reality.
2. Legal basis
The table combines the binding instruments with the policy document that shapes the market outlook. Note that the framework agreement is a policy document and does not create registration obligations directly.
| Instrument | Reference | Publication date | Provisions |
|---|---|---|---|
| Medical Devices Law (Loi n° 84-12) | Dahir n° 1-13-90 | August 30, 2013 | Article 7 (declaration of local manufacturing establishments); Article 12 (certificate issued to manufacturing or importing establishments) |
| Strategic framework agreement for the medical device industry 2026–2030 | No legal reference (government and industry framework agreement) | Signed February 4, 2026 | Local manufacturing, import substitution, investment and export support |
| Law establishing AMMPS (Loi n° 10-22) | Dahir n° 1-23-54 | July 12, 2023 | AMMPS as one of the signatories |
Practical estimate note: the 85%–90% import-dependence figure is an official and industry public statement; industry-scale data (jobs, investment, turnover, value added) comes from Moroccan media reporting and is marked by GRZAN as a practical estimate. The strategic framework agreement is a policy document, not a regulatory text, and does not directly create registration obligations.
3. Expert insights
Insight 1: High import dependence does not mean easy market access. The 85%–90% import share describes the market’s reliance on external supply, but the registration threshold of Article 12 has not been lowered because of it. What genuinely eases access are the six categories of specific authorization under Article 13 and the emergency channel of Article 21; companies should aim at those two provisions rather than waiting for an overall relaxation that the import statistics do not predict. Reading the market numbers as a regulatory signal is a category error, and the projects that clear fastest are the ones built on the authorization provisions that actually exist.
Insight 2: The local manufacturing agreement signals the future, not the present. The agreement runs from 2026 to 2030 and covers four measures: replacing imports with local production, investment and export support, cooperation between Moroccan and international companies, and talent development. The current registration rules have not changed because of the agreement. Nevertheless, when choosing a licensed establishment, companies should give preference to partners with local production or assembly capability, keeping an interface open for future policy benefits instead of having to re-qualify a new partner when incentives arrive.
Insight 3: Article 7 already leaves the door open for local production establishments. The establishment declaration covers manufacturing, import, export and distribution activities. If a Chinese manufacturer sets up a factory or assembly line in Morocco, its local manufacturing establishment can be declared under Article 7 and, under the second paragraph of Article 12, hold the registration certificate directly, bypassing the structural constraint of depending on an importer as the certificate holder. The statute anticipated onshoring before the policy agreement did, and the mechanics are already in place.
Insight 4: The regulatory load concentrates in a small pool of declared establishments. Analysis of the public register verified by GRZAN shows that as of April 30, 2026, the AMMPS register of declared device establishments contained roughly 171 unique active entities, the overwhelming majority of them Moroccan distribution and import companies. This number sizes the pool of available certificate holders for a Chinese manufacturer: the pool is small, so partner selection must start early (the figure comes from third-party analysis of the public register and is a practical estimate).
4. Practical recommendations
- Design the Morocco strategy in three phases. Short term (0–12 months): import registration. Medium term (1–3 years): evaluate local assembly or contract manufacturing. Long term: track the investment and export support measures under the framework agreement.
- Select the certificate holder on capability, not on willingness alone. Prefer establishments whose declared activities include import and that have warehousing and vigilance capability already in place.
- Lock in the partner early. The pool of licensed establishments is limited, and a change requires a transfer authorization under Article 17, so an early wrong choice carries a high correction cost.
- Track the implementing texts of the agreement. The agreement itself creates no registration duties, but derived investment, tax or local-procurement measures, once enacted, materially change the competitive conditions and should trigger a strategy review.
5. Verification checklist
- □ It has been confirmed that the 85%–90% import-dependence figure is a public statement and not a regulatory requirement
- □ The signing date and the signatories of the 2026–2030 strategic framework agreement have been confirmed
- □ The feasibility of an Article 7 establishment declaration under the local-production path has been assessed
- □ Candidate licensed establishments have been checked for the import activity type
- □ The current status of candidate establishments has been checked against the AMMPS register
- □ The project plan distinguishes the short-term import track from the medium-term localization track
- □ A tracking mechanism for the implementing texts of the agreement has been established
Regulatory information verified as of October 30, 2026. GRZAN provides market-entry strategy, licensed-establishment sourcing and registration services for manufacturers entering Morocco, with structured monitoring of the 2026–2030 industry policy framework. For project inquiries, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us